Two different strategies have been applied: HIF-1 upregulation for ischemic diseases (Li et al., 2014) and HIF-1 inhibition for cancer and endometriosis (Zhou et al., 2012; Bhattarai et al., 2017). This evidence concerns the gene HIF1A and cancer.